Vascarta

Vascarta Inc.
Menu
Facebook Linkedin

Media

Joel Friedman: Harnessing An Ancient Remedy Einstein Magazine Winter-Spring 2023

Novel transdermal curcumin therapeutic preserves endothelial barrier function in a high-dose LPS rat model; ARTIFICIAL CELLS, NANOMEDICINE, AND BIOTECHNOLOGY 2023, VOL. 51, NO. 1, 33–40)

Novel Transdermal Curcumin Therapeutic Preserves Endothelial Barrier Function in a Rat Model of Sepsis.

See this video overview of Vascarta’s topical/transdermal curcumin gel formulation

FDA CBER & Vascarta Research Plan – Mechanistic insights into blood storage lesions and the development of antioxidant countermeasures

Press release: TRANSDERMAL CURCUMIN YIELDS PROMISING DATA FOR SICKLE CELL SUFFERERS

Published poster: "Mechanism-based Targeting of Sickle Cell Pathobiology and Pain with Novel Transdermal Curcumin"

Accessibility

Scroll to Top